Stifel Maintains Buy on Dyne Therapeutics, Raises Price Target to $39
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
Stifel analyst Paul Matteis maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and raises the price target from $36 to $39.
Stifel analyst Paul Matteis maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and raises the price target from $36 to $39.